drugset / Trial / NCT03671525

Cognitive Effects of Nimodipine in Patients With Schizophrenia

NCT03671525

Phase 0 Completed 18 enrolled Johns Hopkins University
RandomizedCrossoverQuadruple-blindOther

Summary

This study aims to evaluate the acute effects of nimodipine on cognitive performance in patients with schizophrenia using a battery of cognitive assessments.The subjects will also complete a 30-minute structural and functional MRI scan, with the goal of linking brain activity with working memory performance. Investigators predict that the performance increase induced by nimodipine will be greater in subjects who carry the A allele for the Calcium Voltage-Gated Channel Subunit Alpha1 C (CACNA1C) risk single nucleotide polymorphism (SNP) (rs1006737) in comparison to the response of G carriers.

Timeline

Start
2018-10-05
Primary completion
2023-05-12
Completion
2023-05-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Nimodipine Small molecule 60 mg